The Advancements and Potential of MSD cytokine assay in Mass Spectrometry Services

Meso Scale Discovery Assay is a proprietary platform for measuring cytokines in complex study samples. Meso Scale Discovery (MSD) are multiplex assays that help researchers profile analytes such as intercellular signaling proteins and cytokines, directly impacting human health and drug development studies. MSD cytokine assay combines electrochemiluminescence detection and multiarray technology to offer multiplexing capacities and enhanced sensitivity.

Today, researchers have numerous MSD assay development solutions for assessing analytes in study matrices. These assay formats include a Meso Scale pharmacokinetic assay, MSD cytokine multiplex assay, MSD cell-based assay, MSD biomarker assay, etc. ADA MSD and PK Meso Scale assays are crucial in immunogenicity assay development. Besides, reliable alternatives of MSD custom assay and MSD ELISA conversion kits have made MesoScale ELISA the primary detection technique in drug development studies. 

Any advancements in MSD assays, such as MesoScale cytokine multiplex assay, will help researchers further combine different techniques for assessing drug compounds. One such robust detection technique is mass spectrometry. The current article focuses on how MSD labs can help advance mass spectrometry services. 

Advances in mass spectrometry services

Mass spectrometry is a powerful tool offering high specificity and sensitivity. MS systems have evolved for over a century. They have emerged as a crucial tool in analytical experiments of chemicals and biological samples. The electromagnetic field of MS units processes ions to determine their mass-to-charge ratio, while ion fragmentation provides structural data and identification.

In analytical experiments, a mass spectrometer is often applicable for numerous applications. However, extracting study samples from unknown matrices requires a preliminary separation and extraction method before MS analysis. These methods include liquid chromatography (LC) and gas chromatography (GC). Out of GC and LC units, LC-MS analysis is considered a gold standard in bioanalytical testing. However, LC-MS and GC-MS need a rigorous sample preparation process that is labor, time-consuming, and expensive. These limitations make the real-time use of LC-MS methods in clinical settings a massive challenge. 

Higher cost and technical barriers are the two primary challenges to using MS in a clinical setting. However, the advent of ambient ionization and miniature mass spectrometers provided much-needed relief for its point-of-care applications. The ambient ionization technique focuses on direct MS analysis with few sample preparation steps. On the other hand, miniature mass spectrometers offer the potential to use MS units in any specific analytical setting. 

The ambient ionization technique has been the driving force for assessing complex study materials, such as blood, tissue samples, and urine, directly without multiple preparation and separation steps. Hence, ambient ionization mass spectrometry is widely used for analyzing metabolites, therapeutic drugs, and other bioactive compounds. Besides, it has been the primary reason why non-experts such as physicians and nurses can handle MS technology. 

Furthermore, ambient MS analysis has minimal effect on the sample, making it ideal for analyzing tissue samples. Notably, mass spectrometry imaging further offers an additional dimension to MS analysis. MS imaging provides detailed distribution data of molecules present in the tissue. This information can help researchers differentiate between disease and normal tissues, proving critical for clinical use. In conclusion, any advancements in bioanalytical techniques, such as MSD assays, will remain crucial for complementing the applications of mass spectrometry services.

Read: The Significance of ADA antibody assay in Clinical Trials and the Role of assay development services

Related Articles

Leave a Reply

Back to top button